BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24743367)

  • 1. [A case of advanced gastric cancer in which the serum HER2-ECD level could be used as a biomarker].
    Terakawa H; Oyama K; Watanabe T; Tsukada T; Okamoto K; Kinoshita J; Furukawa H; Makino I; Nakamura K; Hayashi H; Inokuchi M; Nakagawara H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Kitagawa H; Fushida S; Fujimura T; Ohta T
    Gan To Kagaku Ryoho; 2014 Apr; 41(4):491-3. PubMed ID: 24743367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A case of HER2-positive advanced gastric cancer successfully treated with a combination of capecitabine, cisplatin, and trastuzumab as first-line chemotherapy].
    Deguchi K; Nishikawa K; Iwase K; Kawada J; Aono T; Yoshida H; Nomura M; Tamagawa H; Matsuda C; Deguchi T; Higashi S; Okumura Y; Noguchi Y; Nomura M; Takagi M; Fukui A; Tanaka Y
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2253-5. PubMed ID: 24394076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A case of HER2-positive gastric cancer successfully treated with trastuzumab plus capecitabine plus cisplatin chemotherapy as third-line treatment].
    Murata Y; Matsuura T; Kanoshima K; Kuwabara H; Fuyuki A; Tomeno W; Taniguchi R; Uchiyama T; Kuriyama H; Hata Y
    Gan To Kagaku Ryoho; 2013 Jul; 40(7):933-6. PubMed ID: 23863740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy.
    Zhou J; Peng Z; Liu Y; Gong J; Zhang X; Lu M; Gao J; Li Y; Li Y; Shen L
    J Gastroenterol; 2015 Sep; 50(9):955-61. PubMed ID: 25702260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A case of unresectable HER2-positive advanced gastric cancer successfully treated by combination therapy with trastuzumab and paclitaxel].
    Ojima E; Nishimura G; Nishijima K; Futagami F; Nakamura T; Hosokawa A
    Gan To Kagaku Ryoho; 2012 Nov; 39(12):2339-41. PubMed ID: 23268070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum HER2 extracellular domain as a potential alternative for tissue HER2 status in metastatic gastric cancer patients.
    Peng Z; Liu Y; Li Y; Zhang X; Zhou J; Lu M; Li Q; Shen L
    Biomark Med; 2014; 8(5):663-70. PubMed ID: 25123035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case of unresectable Stage IV HER2-positive advanced gastric cancer treated by using trastuzumab combined with chemotherapy].
    Aomatsu N; Doi Y; Takemura S; Tanaka H; Muguruma K; Yui S; Hirakawa K
    Gan To Kagaku Ryoho; 2014 Oct; 41(10):1316-8. PubMed ID: 25335729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re-evaluation of HER2 status in metastatic breast cancer and tumor-marker guided therapy with vinorelbine and trastuzumab.
    Stemmler HJ; Stieber P; Lässig D; Heinemann V
    Onkologie; 2005 Feb; 28(2):95-7. PubMed ID: 15692222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A Case of HER2-Positive Advanced Gastric Cancer with Multiple Liver Metastases Effectively Treated with Trastuzumab, Capecitabine, and Cisplatin Combination Therapy].
    Kuga Y; Kitamura S; Okanobu H; Sakimoto H; Nishida T
    Gan To Kagaku Ryoho; 2016 Oct; 43(10):1211-1214. PubMed ID: 27760940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of SPT therapy( S-1+CDDP+trastuzumab) was successful for HER2-positive gastric cancer accompanied by distant lymph node metastasis].
    Hyuga N; Kobayashi K; Watanabe R; Chono A; Matsumoto T; Takemoto H; Takachi K; Nishioka K; Aoki T; Uemura Y; Yoshida K
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2256-8. PubMed ID: 24394077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Two cases of human epidermal growth factor receptor 2-positive advanced gastric cancer successfully treated with S-1, cisplatin, and trastuzumab combination therapy followed by curative resection].
    Yasuyama A; Mikata S; Soma Y; Yoshikawa Y; Watase C; Kubota M; Miyake Y; Matsuura Y; Kim HM; Murakami M; Hirota M; Morishima H; Matsunami N; Hasegawa J; Miwa H; Nezu R
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2203-6. PubMed ID: 24394060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
    Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
    J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of a patient with HER2-positive metastatic gastric cancer with third-line combination therapy with irinotecan, 5-fluorouracil, leucovorin and trastuzumab (FOLFIRI-T).
    Weissinger F; Reymond M; Dumke K; Krüger M
    Onkologie; 2011; 34(10):548-51. PubMed ID: 21985855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression.
    Dai GH; Shi Y; Chen L; Lv YL; Zhong M
    Hepatogastroenterology; 2012; 59(120):2439-44. PubMed ID: 22534547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A Case of HER2-Positive Stage IV Advanced Gastric Cancer Treated with Chemotherapy Combined with Trastuzumab].
    Takaya K; Takahashi R; Honma S; Horii S; Takahashi H; Hagiwara M; Chin M; Hashizume E
    Gan To Kagaku Ryoho; 2016 Sep; 43(9):1113-6. PubMed ID: 27628555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer.
    Palacio S; Loaiza-Bonilla A; Kittaneh M; Kyriakopoulos C; Ochoa RE; Escobar M; Arango B; Restrepo MH; Merchan JR; Rocha Lima CM; Hosein PJ
    Anticancer Res; 2014 Jan; 34(1):301-6. PubMed ID: 24403478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A Case of HER2-Positive Unresectable Gastric Cancer with Multiple Lymph Node and Liver Metastases Controlled Effectively by Combination Chemotherapy with Capecitabine, Oxaliplatin, and Trastuzumab].
    Sato N; Nakayama A; Takai Y; Kamata T
    Gan To Kagaku Ryoho; 2017 Nov; 44(12):1266-1268. PubMed ID: 29394602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of advanced gastric cancer successfully treated with TS-1/CDDP combination chemotherapy, able to maintain CR for more than two years against multiple liver metastases].
    Meguro E; Kimura T; Noda Y; Matsumoto Y; Irinoda T; Hayakawa Y; Kobayashi M; Takagane A; Hioki J
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):249-52. PubMed ID: 17301537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of trastuzumab and triple FLOT chemotherapy (5-fluorouracil/leucovorin, oxaliplatin, and docetaxel) in patients with HER2-positive metastatic gastric cancer: report of 3 cases.
    Al-Batran SE; Hozaeel W; Jäger E
    Onkologie; 2012; 35(9):505-8. PubMed ID: 23007148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
    Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
    J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.